Video Experimental Relacionado
Updated: Sep 10, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.1K
Biosimilares para el tratamiento de la psoriasis en placas crónica de moderada a grave
Paolo Gisondi1, Francesco Bellinato1, Tea Curic1
1Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
Psoriasis (Auckland, N.Z.)
|August 27, 2025
Resumen
Los medicamentos biosimilares ofrecen una alternativa rentable a los biológicos caros para el tratamiento de la psoriasis de moderada a grave. Estos productos biológicos muy similares garantizan una seguridad y eficacia comparables, mejorando el acceso de los pacientes y reduciendo los costes de atención sanitaria.
Área de la Ciencia:
- Dermatología
- Inmunología
- Farmacoeconomía
Sus antecedentes:
- La psoriasis es una enfermedad inflamatoria crónica de la piel que afecta a millones de personas en todo el mundo.
- El tratamiento sistémico está indicado para la psoriasis de moderada a grave que afecta a áreas críticas del cuerpo.
- Las terapias biológicas y de pequeñas moléculas han mejorado la calidad de vida, pero son costosas.
Objetivo del estudio:
- Revisar los medicamentos biosimilares para el tratamiento de la psoriasis.
- Destacar las ventajas potenciales de los biosimilares en cuanto a ahorro de costes.
- Para discutir agentes biológicos específicos y sus biosimilares.
Principales métodos:
- Revisión narrativa de la literatura existente.
- Centrarse en las terapias biológicas aprobadas para la psoriasis.
- Análisis de los conceptos de biosimilares y sus implicaciones en materia de costes.
Principales resultados:
- Los biosimilares son muy similares a los biológicos de referencia en seguridad, pureza y eficacia.
- Los biosimilares pueden reducir los gastos de salud.
- Se puede lograr un mayor acceso a tratamientos avanzados para la psoriasis.
Conclusiones:
- Los biosimilares representan una oportunidad significativa para mejorar el acceso a tratamientos efectivos para la psoriasis.
- La adopción de biosimilares puede aliviar las cargas financieras de los sistemas sanitarios.
- Se requiere una discusión más detallada sobre los biosimilares específicos como el adalimumab, el infliximab, el etanercept y el ustekinumab.
Videos de Conceptos Relacionados
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
252
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
252
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
202
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
202
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
01:29Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
01:29Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189